Ellis Investment Partners’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.9M | Buy |
7,558
+29
| +0.4% | +$6.24K | 0.29% | 69 |
|
|
2026
Q1 | $1.64M | Buy |
7,529
+77
| +1% | +$17.1K | 0.28% | 77 |
|
|
2025
Q4 | $1.7M | Buy |
7,452
+29
| +0.4% | +$6.61K | 0.3% | 77 |
|
|
2025
Q3 | $1.72M | Sell |
7,423
-316
| -4% | -$64.3K | 0.31% | 72 |
|
|
2025
Q2 | $1.44M | Buy |
7,739
+67
| +0.9% | +$12.5K | 0.28% | 72 |
|
|
2025
Q1 | $1.61M | Buy |
7,672
+422
| +6% | +$82K | 0.33% | 66 |
|
|
2024
Q4 | $1.29M | Sell |
7,250
-46
| -0.6% | -$8.46K | 0.25% | 81 |
|
|
2024
Q3 | $1.44M | Sell |
7,296
-1,136
| -13% | -$212K | 0.28% | 72 |
|
|
2024
Q2 | $1.45M | Buy |
8,432
+227
| +3% | +$37.6K | 0.31% | 67 |
|
|
2024
Q1 | $1.49M | Sell |
8,205
-1,411
| -15% | -$243K | 0.32% | 64 |
|
|
2023
Q4 | $1.49M | Sell |
9,616
-133
| -1% | -$19.4K | 0.35% | 64 |
|
|
2023
Q3 | $1.45M | Sell |
9,749
-2,635
| -21% | -$387K | 0.37% | 64 |
|
|
2023
Q2 | $1.67M | Sell |
12,384
-2,136
| -15% | -$313K | 0.41% | 62 |
|
|
2023
Q1 | $2.31M | Sell |
14,520
-1,416
| -9% | -$216K | 0.6% | 44 |
|
|
2022
Q4 | $2.58M | Sell |
15,936
-1,197
| -7% | -$184K | 0.7% | 38 |
|
|
2022
Q3 | $2.3M | Sell |
17,133
-6,008
| -26% | -$862K | 0.64% | 38 |
|
|
2022
Q2 | $3.54M | Sell |
23,141
-6,289
| -21% | -$961K | 0.95% | 22 |
|
|
2022
Q1 | $4.77M | Sell |
29,430
-7,159
| -20% | -$1.04M | 1.12% | 19 |
|
|
2021
Q4 | $4.95M | Buy |
36,589
+275
| +0.8% | +$32.5K | 1.14% | 18 |
|
|
2021
Q3 | $3.92M | Buy |
36,314
+11
| +0% | +$1.26K | 0.99% | 21 |
|
|
2021
Q2 | $4.09M | Buy |
36,303
+234
| +0.6% | +$26.4K | 1.04% | 21 |
|
|
2021
Q1 | $3.9M | Sell |
36,069
-19
| -0.1% | -$2.03K | 1.09% | 19 |
|
|
2020
Q4 | $3.87M | Buy |
36,088
+8
| +0% | +$769 | 1.17% | 17 |
|
|
2020
Q3 | $3.16M | Buy |
36,080
+848
| +2% | +$79.8K | 1.11% | 17 |
|
|
2020
Q2 | $3.49M | Buy |
35,232
+2,569
| +8% | +$226K | 1.31% | 14 |
|
|
2020
Q1 | $2.4M | Sell |
32,663
-82
| -0.3% | -$6.99K | 1.14% | 17 |
|
|
2019
Q4 | $2.93M | Sell |
32,745
-672
| -2% | -$55.8K | 0.98% | 19 |
|
|
2019
Q3 | $2.45M | Buy |
33,417
+694
| +2% | +$47.6K | 0.89% | 23 |
|
|
2019
Q2 | $2.4M | Sell |
32,723
-736
| -2% | -$57.8K | 0.9% | 22 |
|
|
2019
Q1 | $2.7M | Sell |
33,459
-836
| -2% | -$68.4K | 1.09% | 19 |
|
|
2018
Q4 | $3.16M | Buy |
+34,295
| New | +$3.02M | 1.44% | 13 |
|
Other funds holding ABBV
Ellis Investment Partners's ABBV Position: Q2 2026 in Review
Ellis Investment Partners increased its AbbVie (ABBV) stake by 0.39% in Q2 2026, buying an estimated $6.24K and bringing the position to 7,558 shares worth $1.9M. The position accounts for 0.29% of the portfolio, ranked #69.
Ellis Investment Partners first reported a position in ABBV in Q4 2018 and has held it in 31 quarters since. The position peaked at $4.95M in Q4 2021. 4,201 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- Ellis Investment Partners held 7,558 shares of AbbVie worth $1.9M as of Q2 2026.
- Ellis Investment Partners bought 29 AbbVie shares in Q2 2026, an estimated $6.24K.
- AbbVie made up 0.29% of Ellis Investment Partners's portfolio in Q2 2026, its #69 holding.
- Ellis Investment Partners first reported a position in AbbVie in Q4 2018 and has held it in 31 quarters since.
- Ellis Investment Partners's AbbVie position peaked at $4.95M in Q4 2021.
- 4,201 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on Ellis Investment Partners's 13F filing for Q2 2026, filed 5 Aug 2026.